Home Cart 0 Sign in  

[ CAS No. 163706-58-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 163706-58-9
Chemical Structure| 163706-58-9
Structure of 163706-58-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 163706-58-9 ]

Related Doc. of [ 163706-58-9 ]

Alternatived Products of [ 163706-58-9 ]

Product Details of [ 163706-58-9 ]

CAS No. :163706-58-9 MDL No. :MFCD15832982
Formula : C16H22F3N5O4S2 Boiling Point : -
Linear Structure Formula :- InChI Key :ZGVUPMJCZYBIDI-IDTAVKCVSA-N
M.W : 469.50 Pubchem ID :10600409
Synonyms :

Calculated chemistry of [ 163706-58-9 ]

Physicochemical Properties

Num. heavy atoms : 30
Num. arom. heavy atoms : 9
Fraction Csp3 : 0.69
Num. rotatable bonds : 10
Num. H-bond acceptors : 10.0
Num. H-bond donors : 4.0
Molar Refractivity : 106.31
TPSA : 176.15 Ų

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.53 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.72
Log Po/w (XLOGP3) : 2.3
Log Po/w (WLOGP) : 2.0
Log Po/w (MLOGP) : -0.48
Log Po/w (SILICOS-IT) : 0.84
Consensus Log Po/w : 1.48

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 1.0
Egan : 1.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.76
Solubility : 0.0812 mg/ml ; 0.000173 mol/l
Class : Soluble
Log S (Ali) : -5.64
Solubility : 0.00108 mg/ml ; 0.00000231 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -2.97
Solubility : 0.503 mg/ml ; 0.00107 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 4.71

Safety of [ 163706-58-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 163706-58-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 163706-58-9 ]
  • Downstream synthetic route of [ 163706-58-9 ]

[ 163706-58-9 ] Synthesis Path-Upstream   1~8

  • 1
  • [ 163706-57-8 ]
  • [ 163706-58-9 ]
YieldReaction ConditionsOperation in experiment
75% With potassium carbonate In isopropyl alcohol for 2 h; Reflux The crude product obtained in Example 38 (60.3 g)And potassium carbonate (199g, 1.44mol)Added to 600 ml of isopropanol,Heat to reflux for 2 h. Concentrate to dryness under reduced pressure, add 300ml water, acetic acid to adjust the pH ~ 7,After stirring 0.5 h, the mixture was filtered and the filter cake was dried to give 33.8 g of pale yellow solid.The three-step total yield was 75percent (based on the compound of formula (10)) and the HPLC purity was 97.9percent.
33.8 g With potassium carbonate In isopropyl alcohol for 2 h; Reflux The crude product obtained in Example 38 (60.3 g) and potassium carbonate (199 g, 1.44 mol) were added to 600 ml of isopropanol and heated under reflux for 2 h. The mixture was concentrated to dryness under reduced pressure, 300 ml of water was added, and the pH was adjusted to 7 with acetic acid. After stirring for 0.5 h, the filter cake was dried to give a yellowish color.33.8 g of color solid, 75percent overall yield over three steps (based on compound of formula (10)),HPLC purity 97.9percent.
Reference: [1] Patent: CN107973798, 2018, A, . Location in patent: Paragraph 0259; 0264; 0265-0267; 0270; 0273
[2] Journal of Medicinal Chemistry, 1999, vol. 42, # 2, p. 213 - 220
[3] Patent: CN107973832, 2018, A, . Location in patent: Paragraph 0028; 0253-0270
  • 2
  • [ 69412-76-6 ]
  • [ 163706-58-9 ]
YieldReaction ConditionsOperation in experiment
9 g
Stage #1: With sodium hydride In N,N-dimethyl-formamide at 0 - 5℃; for 0.5 h;
Stage #2: at 70 - 80℃; for 2.5 h;
Sodium hydride (4.2 g, 0.105 mol) was added to a solution of DMF (30 mL) and then at 0~5 ° C,The compound 3,3,3-trifluoropropanethiol prepared in Example 6 was added(8g, 0.06mol), the reaction was stirred for half an hour while maintaining the temperature,A solution of compound VII obtained in Example 7 in DMF (20 mL)After the addition was completed, the reaction solution was warmed to 70~80 ° C and incubated for 2.5 hours to complete the reaction. The reaction solution was cooled to room temperature,Water (100 mL) was added, a yellow solid was precipitated, suction filtered,The filter cake was recrystallized from a mixed solution of ethanol (40 mL) and water (30 mL), and suction-filtered to give TEPAD, a known canonical intermediate of cangrelor, Compound I: 9 g, HPLC purity 99.9percent The six-step total molar yield of TEPAD, a known key intermediate to cangrelor, was 36.7percent.
Reference: [1] Patent: CN106397516, 2017, A, . Location in patent: Paragraph 0059; 0106; 0107; 0108; 0109
  • 3
  • [ 163706-51-2 ]
  • [ 163706-58-9 ]
Reference: [1] Journal of Medicinal Chemistry, 1999, vol. 42, # 2, p. 213 - 220
[2] Patent: CN105273025, 2016, A,
[3] Patent: CN105273026, 2016, A,
[4] Patent: CN105273027, 2016, A,
[5] Patent: CN105949258, 2016, A,
[6] Patent: CN105949258, 2016, A,
  • 4
  • [ 163706-52-3 ]
  • [ 163706-58-9 ]
Reference: [1] Journal of Medicinal Chemistry, 1999, vol. 42, # 2, p. 213 - 220
[2] Patent: CN107973798, 2018, A,
[3] Patent: CN107973798, 2018, A,
[4] Patent: CN107973798, 2018, A,
  • 5
  • [ 43157-50-2 ]
  • [ 163706-58-9 ]
Reference: [1] Journal of Medicinal Chemistry, 1999, vol. 42, # 2, p. 213 - 220
[2] Patent: CN105949258, 2016, A,
[3] Patent: CN105949258, 2016, A,
  • 6
  • [ 187668-44-6 ]
  • [ 163706-58-9 ]
Reference: [1] Patent: CN105061431, 2017, B,
  • 7
  • [ 3056-18-6 ]
  • [ 163706-58-9 ]
Reference: [1] Patent: CN106397516, 2017, A,
  • 8
  • [ 16321-99-6 ]
  • [ 163706-58-9 ]
Reference: [1] Patent: CN106397516, 2017, A,
Same Skeleton Products
Historical Records